Full Answer
Where can I buy Onconova Therapeutics stock?
Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.76.
What is Onconova’s transfer agent?
Onconova’s transfer agent, EQ Shareowner Services, will provide instructions to stockholders of record regarding the process for exchanging share certificates and all book-entry or other electronic positions representing issued and outstanding shares of Onconova common stock will be automatically adjusted.
How does the reverse stock split work at Onconova?
Upon effectiveness of the reverse stock split, each fifteen shares of Onconova’s common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share.
Who is the new director of Corporate Development at Onconova?
NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.
Why is onconova stock dropping?
Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
Should I buy onconova Therapeutics?
Onconova Therapeutics has 682.61% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
Will onconova Therapeutics stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +691.37% increase from the last price of 1.39.
Why is ONTX going down?
The decrease was primarily related to the Company's focus on its Phase 1 program with narazaciclib, following the completion of the Phase 3 INSPIRE study in 2020. General and administrative expenses were $9.4 million for 2021, compared with $8.3 million for 2020.
Is ORTX a good stock to buy?
Out of 4 analysts, 1 (25%) are recommending ORTX as a Strong Buy, 1 (25%) are recommending ORTX as a Buy, 1 (25%) are recommending ORTX as a Hold, 0 (0%) are recommending ORTX as a Sell, and 1 (25%) are recommending ORTX as a Strong Sell. What is ORTX's earnings growth forecast for 2022-2024?
Will ONTX reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021.
Is frequency Therapeutics a good stock to buy?
Frequency Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Is ONTX a decent stock?
The financial health and growth prospects of ONTX, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
What does onconova therapeutics do?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Should I buy or sell Onconova Therapeutics stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There a...
What is Onconova Therapeutics' stock price forecast for 2022?
3 brokerages have issued 1 year price targets for Onconova Therapeutics' stock. Their forecasts range from $7.00 to $12.00. On average, they antici...
How has Onconova Therapeutics' stock price performed in 2022?
Onconova Therapeutics' stock was trading at $2.55 on January 1st, 2022. Since then, ONTX shares have decreased by 47.8% and is now trading at $1.33...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 65,800 shares, a decr...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast f...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0....
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number o...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Dr. Steven M. Fruchtman M.D. , CEO, Pres & Director (Age 71, Pay $903.45k)...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Greenwich LifeSciences (GLSI) , Evelo Biosciences (EVLO) , Epizyme (EPZM) , Da...
Is Onconova Therapeutics stock a Buy, Sell or Hold?
Onconova Therapeutics stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 1 hold ratings, and...
What was the 52-week low for Onconova Therapeutics stock?
The low in the last 52 weeks of Onconova Therapeutics stock was 1.00. According to the current price, Onconova Therapeutics is 143.00% away from th...
What was the 52-week high for Onconova Therapeutics stock?
The high in the last 52 weeks of Onconova Therapeutics stock was 7.99. According to the current price, Onconova Therapeutics is 17.90% away from th...
What are analysts forecasts for Onconova Therapeutics stock?
The 1 analysts offering price forecasts for Onconova Therapeutics have a median target of 7.00, with a high estimate of 7.00 and a low estimate of...
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
Is Onconova's expectations reasonable?
Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
How much was the General and Administrative expenses in 2021?
General and administrative expenses were $2.2 million for the first quarter of 2021, compared with $1.8 million for the first quarter of 2020. The increase was primarily related to higher special stockholder meeting by proxy expenses and insurance costs in the 2021 period.
How much is research and development in 2021?
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020. The decrease was primarily related to lower expenses for the oral rigosertib combination program and the completed Phase 3 INSPIRE study in the 2021 period.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
48 Biggest Movers From Friday
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.
What is Onconova Therapeutics?
What: Shares of Onconova Therapeutics ( NASDAQ:ONTX), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the interim results of its late-stage metastatic pancreatic cancer study .
Is Onconova discontinuing Gemzar?
So what: According to Onconova's press release, which came out after the closing bell yesterday, Onconova is discontinuing its late-stage study of intravenous rigosertib in combination with Eli Lilly 's Gemzar in treating front-line metastatic cancer.
